

## Antimicrobial activity of novel 3-substituted- 5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione derivatives

K. K. Oza, H. S. Patel\*

Department of Chemistry, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India

Received May 7, 2009; Revised October 3, 2009

5-(Pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione was prepared from isonicotinic acid hydrazide (isoniazid). The Mannich reaction of 5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione was carried out with formaldehyde and various 1-substituted piperazine derivatives. All the synthesized compounds were characterized by IR and  $^1\text{H}$  NMR spectral feature. Their thiol-thione tautomeric equilibrium is described. All the compounds were also screened for their antimicrobial activity.

**Key words:** Isonicotinic acid hydrazide, 1,3,4-oxadiazole-2-thione, Mannich base reaction, spectral studies, antimicrobial activity.

### INTRODUCTION

Many drugs like antibiotics, antimycotics, circulatory system and antiparasitic ones contain piperazine ring [1–7]. Thus piperazine derivatives play the pivotal role in therapeutical application. 1,3,4-oxadiazole-2-thione has been reported to exhibit antifungal, antibacterial, antileishmanial and insecticidal activities [8–13]. One of the anti-TB drugs i.e. isoniazide affords heterocyclic compounds, which have good biological properties [14]. Its Mannich bases were also reported recently for important biological properties [15]. In view of the important biological properties it was planned to synthesize Mannich bases with 5-(pyridin-4-yl)-3H-1,3,4-oxadiazole-2-thione with piperazine moiety. The route is given in Scheme 1.

### EXPERIMENTAL

Melting points were determined by the open capillary method and were uncorrected. The IR spectra were recorded in KBr pellets on a Nicolet 760D spectrometer and  $^1\text{H}$  NMR spectra were recorded in DMSO with TMS as internal standard on a Bruker spectrometer at 400 MHz.

*Preparation of 5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione (2).* Compound (2) was prepared according to a reported method [16]. A mixture of 1 (0.01 mol), potassium hydroxide (0.015 mol), Carbon disulphide (0.015 mol) and ethanol (50 ml, 95%), was refluxed for 6 h. Excess of solvent was distilled off and the remaining residue was poured in ice cold water and acidified with acetic acid. The

yellow coloured compound, thus obtained, was filtered and dried.

*Preparation of 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione (3a–i).* Compounds (3a–i) were prepared by a known method [15]. Amount of 5.6 mmol of substituted piperazine derivatives were added to mixture of 5.6 mmol of 2 in 30 ml of absolute ethanol. Portion of 5.6 mmol 37% formaldehyde were added dropwise to the above stirred suspension and the reaction mixture was heated under reflux for 24 h. After concentration under reduced pressure, the residue was recrystallized from absolute ethanol.

*Preparation of S-methyl-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione (4).* Compound (4) was prepared according to known method [17]. A mixture of 2 (0.005 mol), sodium hydroxide (0.005 mol) and methyl iodide (0.006 mol) was stirred in water for 14 h. The resulting solution was removed by vacuum evaporation, the products were collected by filtration and washed with water.

### BIOLOGICAL SCREENING

#### *Antibacterial activities*

Antibacterial activities of all the compounds were studied against Gram-positive (*Staphylococcus aureus*, *Bacillus subtilis*) and Gram-negative (*E. coli*, *Salmonella typhi*), at a concentration of 50  $\mu\text{g}/\text{ML}$  by agar cup plate method. A DMSO system was used as a control in this method. Under similar conditions, using tetracycline as a standard for comparison, we carried out a control experiment. The area of inhibition of zone was measured in mm. Compounds 3d and 3e were found to be more active

\* To whom all correspondence should be sent:  
E-mail: drhspatel786@yahoo.com

against the above microbes. Other compounds were found to be less or moderately active than tetracycline. (Table 2).

#### Antifungal activities

The antifungal activities of all the compounds were studied at 1000 ppm concentration *in vitro*. Plant pathogenic organisms used were *Nigrospora Sp.*, *Aspergillus niger*, *Rhizopus nigricum*, *Botrydoplada thiorbomine* and *Penicillium expansum*. The antifungal activity of all compounds was measured on each of these plant pathogenic strains on a potato dextrose agar (PDA) medium. Such a PDA medium contained potato 200 g, dextrose 20 g, and agar 20 g and 1 L of water. Five day old cultures were employed. The compounds to be tested were suspended (1000 ppm) in a PDA medium and autoclaved at 120°C for 15 min at 15 atm pressure. These media were poured into sterile Petri plates and the organisms were inoculated after cooling down the Petri plates. The percentage inhibition for fungi was calculated after five days using the formula given below:

$$\text{Percentage of inhibition} = 100(X-Y)/X$$

where X = area of colony in control plate; and Y =


area of colony in test plate.

The fungicidal activity displayed by various compounds is shown in Table 3.

#### RESULTS AND DISCUSSION

The Mannich base reaction of 5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione has been performed successfully with 1-substituted piperazine derivatives. Both moieties have important applications in medicine. The structure of 3-substituted- 5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-thione was confirmed by elemental analysis and IR spectra showing absorption bands at 1625–1645  $\text{cm}^{-1}$  (C=N), 1240–1260  $\text{cm}^{-1}$  (C=S), 1040–1080  $\text{cm}^{-1}$  (C–O), 3035–3085  $\text{cm}^{-1}$  (C–H of Ar), 1480–1525  $\text{cm}^{-1}$  (C=C of Ar), 1040–1080  $\text{cm}^{-1}$  (N–N of 1,3,4-oxadiazole-2-thione). Additional bands appear due to substitution in the piperazine moiety, as follows: 1520  $\text{cm}^{-1}$  ( $-\text{NO}_2$ ), 2830  $\text{cm}^{-1}$  ( $-\text{CH}$  of  $-\text{OCH}_3$ ), 3550  $\text{cm}^{-1}$  ( $-\text{OH}$ ).

The examination of the data reveals that the elemental contents (Table 1) are consistent with the predicted structure shown in Scheme 1. The IR and NMR data (Table 1) also allow a direct assignment of the predicted structure.



Scheme 1

**Table 1.** Analytical spectral data of compounds **2**, (**3a-i**) and **4**.

Comp.	Molecular formula (mol. mass)	Yield %	M.P., °C	Elemental analysis, % Found (Calcd)				1H NMR $\delta$ , ppm
				C	H	N	S	
<b>2</b>	C <sub>7</sub> H <sub>5</sub> N <sub>3</sub> OS (179.20)	69	262	46.90 (46.92)	2.77 (2.81)	23.40 (23.45)	17.82 (17.89)	8.02 (d, 2H, Pyr.), 8.77 (d, 2H, pyr.), 14.14 (s, 1H, -NH), 1.9 (s, 1H, SH)
<b>3a</b>	C <sub>17</sub> H <sub>18</sub> N <sub>6</sub> OS (354.44)	58	102–103	54.00 (54.02)	4.28 (4.34)	23.60 (23.62)	12.00 (12.02)	8.02, 8.77 (four d, 8H, Ar-H.), 5.03 (s, 2H CH <sub>2</sub> exocyclic), 2.50, 3.19 (two t, 8H, pip.)
<b>3b</b>	C <sub>20</sub> H <sub>23</sub> N <sub>5</sub> OS (381.49)	60	103–105	62.90 (62.97)	6.00 (6.08)	18.30 (18.36)	8.35 (8.41)	8.00, 8.65 (two d, 4H, Ar-H.), 7.03–7.50 (m, 3H, Ar-H.), 4.95 (s, 2H CH <sub>2</sub> exocyclic), 2.48, 3.15 (two t, 8H, pip.)
<b>3c</b>	C <sub>18</sub> H <sub>18</sub> N <sub>6</sub> O <sub>3</sub> S (398.44)	60	174–176	54.21 (54.26)	4.50 (4.55)	20.89 (21.09)	7.90 (8.05)	8.12, 8.87 (two d, 4H, Ar-H.), 7.03–7.50 (m, 4H, Ar-H.), 5.02 (s, 2H CH <sub>2</sub> exocyclic), 2.52, 3.17 (two t, 8H, pip.)
<b>3d</b>	C <sub>19</sub> H <sub>21</sub> N <sub>5</sub> O <sub>2</sub> S (383.47)	63	116–118	59.50 (59.51)	5.4 (5.52)	18.21 (18.26)	8.30 (8.36)	8.02, 8.77 (two d, 4H, Ar-H.), 7.02–8.00 (m, 4H, Ar-H.), 5.11 (s, 2H CH <sub>2</sub> exocyclic), 2.52, 3.17 (two t, 8H, pip.), 3.10 (s, 3H -OCH <sub>3</sub> )
<b>3e</b>	C <sub>18</sub> H <sub>19</sub> N <sub>5</sub> O <sub>2</sub> S (369.44)	55	111–115	58.50 (58.52)	5.10 (5.18)	18.90 (18.96)	8.60 (8.68)	8.05, 8.75 (two d, 4H, Ar-H.), 7.02–8.77 (m, 4H, Ar-H.), 4.99 (s, 2H CH <sub>2</sub> exocyclic), 2.44, 3.11 (two t, 8H, pip.), 6.90 (s, H -OH)
<b>3f</b>	C <sub>15</sub> H <sub>21</sub> N <sub>5</sub> OS (319.43)	70	182–184	56.38 (56.40)	6.59 (6.63)	21.89 (21.92)	9.92 (10.04)	8.02, 8.77 (two d, 4H, Ar-H.), 5.11 (s, 2H CH <sub>2</sub> exocyclic), 2.52, 3.17 (two t, 8H, pip.), 2.69 (m, 1H -CH), 1.3 (m, 6H, -CH <sub>3</sub> )
<b>3g</b>	C <sub>16</sub> H <sub>17</sub> N <sub>7</sub> OS (355.42)	65	139–141	53.99 (54.07)	4.79 (4.82)	27.59 (27.50)	9.00 (9.02)	8.02, 8.77 (two d, 4H, Ar-H.), 7.00–7.80 (m, 3H, Ar-H.), 5.10 (s, 2H CH <sub>2</sub> exocyclic), 2.59, 3.24 (two t, 8H, pip.)
<b>3h</b>	C <sub>14</sub> H <sub>19</sub> N <sub>5</sub> OS (305.40)	65	134–136	55.00 (55.06)	4.95 (4.88)	22.93 (22.90)	10.50 (10.48)	8.01, 8.71 (two d, 4H, Ar-H.), 5.05 (s, 2H CH <sub>2</sub> exocyclic), 2.52, 3.17 (two t, 8H, pip.), 2.38 (m, 2H -CH <sub>2</sub> ), 1.1 (t, 3H, -CH <sub>3</sub> )
<b>3i</b>	C <sub>15</sub> H <sub>21</sub> N <sub>5</sub> OS (319.43)	63	93–98	56.35 (56.40)	6.59 (6.63)	21.90 (21.92)	10.04 (10.00)	8.02, 8.77 (two d, 4H, Ar-H.), 5.05 (s, 2H CH <sub>2</sub> exocyclic), 2.52, 3.17 (two t, 8H, pip.), 1.2 (t, 3H, CH <sub>3</sub> ), 1.5 (m, 2H, CH <sub>2</sub> ), 3.3 (t, 2H, CH <sub>2</sub> )
<b>4</b>	C <sub>8</sub> H <sub>7</sub> N <sub>3</sub> OS (193.23)	50	130–132	49.70 (49.73)	3.59 (3.65)	21.70 (21.75)	16.50 (16.59)	8.00, 8.70 (two d, 4H, Ar-H.), 2.8 (s, 3H, CH <sub>3</sub> )

**Table 2.** Antibacterial activity of compounds (**3a-i**) and **4**.

Comp.	Gram-positive		Gram-negative	
	<i>Staphylococcus aureus</i>	<i>Bacillus subtilis</i>	<i>E. coli</i>	<i>Salmonella typhi</i>
<b>3a</b>	25	21	20	23
<b>3b</b>	22	23	22	19
<b>3c</b>	31	22	28	27
<b>3d</b>	45	46	44	41
<b>3e</b>	41	40	40	43
<b>3f</b>	29	27	26	28
<b>3g</b>	19	17	22	23
<b>3h</b>	21	22	25	30
<b>3i</b>	20	19	23	26
<b>4</b>	22	23	19	21
Tetracycline	40	41	42	39

**Table 3.** Antifungal activity of compounds (**3a-i**) and **4**.

Comp.	Zone of Inhibition at 1000 ppm, %				
	<i>Nigrospora Sp.</i>	<i>Aspergillus niger</i>	<i>Botrydoplodia thiobromine</i>	<i>Rhizopus nigricum</i>	<i>Penicillium expansum</i>
<b>3a</b>	15	19	20	21	22
<b>3b</b>	21	23	15	14	20
<b>3c</b>	34	33	29	30	30
<b>3d</b>	46	46	41	40	40
<b>3e</b>	40	42	42	40	40
<b>3f</b>	22	26	22	29	30
<b>3g</b>	19	18	21	20	18
<b>3h</b>	18	17	20	23	25
<b>3i</b>	28	23	25	21	24
<b>4</b>	26	21	22	28	24

There are some studies on electronic structures and thiol-thione tautomeric equilibria of heterocyclic thione derivatives [18–20]. We observed that extensive thiol-thione tautomerism exists in compound **2**. In the 1H NMR signals of the SH protons were recorded although they were very weak and also the ready synthesis of the Mannich bases **3a-i** and compound **4** confirmed the tautomerism. It has been reported that the crystal structure of com-

pounds like **2** corresponds to the thiol form too [21–23]. Finally, the crystal structure of **2** corresponded to the thione form, but there is thiol-thione tautomerism in solution.

The antibacterial activity of compounds was tested against some strains of bacteria. The results show that the prepared compounds are toxic or moderately toxic against the bacteria. The comparison of the antibacterial activity of some com-

pounds with tetracycline shows that these compounds have almost similar activity.

#### REFERENCES

1. W. Kostowski, *Farmakologia. Podstawy Farmakoterapii*, Wydawnictwo Lekarskie, Warszawa, 1998.
2. A. Chmiel, S. Grudzinski, *Biotechnologia i Chemia Antybiotykow*, PWN, Warszawa, 1998.
3. M. Hepperle, J. Eckert, D. Gala, *Tetrahedron Lett.*, **40**, 5655 (1999).
4. J. Eckert, Ch. Tze-Ming, R. M. Osterman, J. B. Lambert, D. Gala, *Tetrahedron Lett.*, **40**, 566, (1999).
5. C. D. Eldred, B. Evans, S. Hindley, *J. Med. Chem.*, **37**, 3882 (1994).
6. J. H. van Maarseveen, J. A. den Hartog, *Bioorg. Med. Chem. Lett.*, **8**, 1531 (1998).
7. E. van Heyningen, C. N. Brown, *J. Med. Chem.*, **8**, 174 (1965).
8. B. S. Holka, K. N. Poojary, B. Kalluraya, P. V. Gowda, *J. Heterocyclic Chem.*, **5**, 276 (1995).
9. T. Ramalingam, A. A. Deshmukh, P. B. Sattur, *J. Indian Chem. Soc.*, **58**, 269 (1981).
10. J. Hazarkia, J. C. S. Katakya, *Indian J. Heterocyclic Chem.*, **7**, 197 (1998).
11. R. S. Varma, P. Varma, *Indian J. Heterocyclic Chem.*, **6**, 171 (1997).
12. R. S. Varma, V. Bajpai, A. Kapil, *Indian J. Heterocyclic Chem.*, **8**, 281 (1999).
13. R. Iqbal, N. H. Rama, N. Ahmed, K. Zamani, S. Ebrahim, N. Iqbal, *Indian J. Chem.*, **37B**, 506 (1998).
14. *Indian Pharmacopoeia*, Government of India, Ministry of Health and Family Welfare, Delhi, 1996.
15. M. G. Mamolo, D. Zampieri, L. Vio, M. Fermeglia, M. Ferrone, S. Pricl, G. Scialino E. Banfi, *Bioorg. Med. Chem.*, **13**, 3797 (2005).
16. F. Aydogan, Z. Turgut, N. Olcay, S. S. Erdem, *Turk. J. Chem.* **26**, 159 (2002).
17. D. A. Charistos, G. V. Vagenes, L. C. Tzavellas, C. A. Tsoleridis, N. A. Rodios, *J. Heterocycl. Chem.*, **31**, 1593 (1994).
18. C. A. Tsoleridi, D. A. Charistos, G. V. Vagenes, *J. Heterocycl. Chem.* **34**, 1715 (1997).
19. S. Ozturk, M. Akkurt, A. Cansiz, A. Cetin, M. Sekerci, F. W. Heinemann, *Acta Cryst.*, **E 60**, 0322, (2004).
20. S. Ozturk, M. Akkurt, A. Cansiz, M. Koparir, M. Sekerci, F. W. Heinemann, *Acta Cryst.*, **E 60**, 0425 (2004).
21. S. Ozturk, M. Akkurt, A. Cansiz, M. Koparir, M. Sekerci, F. W. Heinemann, *Acta Cryst.*, **E 60**, 0642 (2004).
22. M. S. Y. Khan, G. Chawla, M. A. Mueed, *Indian J. Chem.*, **43B**, 1302 (2004).
- M. Koparir, A. Cetin, A. Canasiz, *Molecules*, **10**, 475 (2005).

#### АНТИМИКРОБНА АКТИВНОСТ НА НОВИ 3-ЗАМЕСТЕНИ 5-(ПИРИДИН-4-ИЛ)-3Н-1,3,4-ОКСАДИАЗОЛ-2-ТИОНОВИ ПРОИЗВОДНИ

К. К. Оза, Х. С. Пател\*

*Химически департамент, Университет „Сардар Пател“, Валаб Видянагар, Гуджарат, Индия*

Постъпила на 7 май 2009 г.; Преработена на 3 октомври 2009 г.

(Резюме)

Синтезиран е 5-(пиридин-4-ил)-3Н-1,3,4-оксадиазол-2-тион от хидразид на изоникотинова киселина (изониазид). Проведена е реакция на Маних на синтезираното съединение с формалдехид и различни 1-заместени пиперазинови производни. Всички синтезирани съединения са охарактеризирани с ИЧС и <sup>1</sup>Н ЯМР. Описано е тяхното тавтомерно равновесие тиол-тион. Всички съединения са изследвани за антимикробна активност.